

# Timothy Sargis

1818 W Ellen St., Chicago, IL 60622  
T: (949) 610-4836 • E: [tsargis@gmail.com](mailto:tsargis@gmail.com)  
[www.timothysargis.com](http://www.timothysargis.com)

## Qualifications

In addition to excelling in academics, I have worked on a variety of projects regarding the discovery and development of novel therapeutics. Through these experiences, I have demonstrated my ability to be a quick learner and a problem solver. At Pfizer and Sanford-Burnham-Prebys, I worked on an inter-disciplinary team and contributed to the development of next generation ALK inhibitors and HIF-2 inhibitors. At both research organizations I used my scientific and communication skills to present creative solutions to optimize experiments in all studies.

## Technical Skills

- Cell Culture
- CTG/XTT Cell Viability Assay
- CRISPR/Cell Line Development
- Viral Transduction
- Western Blotting
- DNA/RNA Purification
- RiboTag Mouse Models
- siRNA/DNA Transfection

## Education

**University of Illinois, Chicago**  
Ph.D. Student (Physiology and Biophysics)

**August 2017 – Current**

**University of California, San Diego**  
B.S. Marine Biology

**September 2014**

## Experience

**Sanford-Burnham-Prebys Medical Discovery Institute**  
Research Assistant II

**January 2015 – July 2017**

Supported the laboratory of Dr. Garth Powis in identifying novel drug candidates that target the hypoxia pathway by inhibiting HIF-2 in clear renal cell carcinoma. Studied the role of HAF overexpression and its relationship to sorafenib resistance. Established how HAF loss leads to the spontaneous development of hepatocellular carcinoma. Designed and performed reporter and viability based assays to identify new drug-like molecules. Performed western blots to characterize target inhibition. Generated and maintained mammalian tumor cell lines.

**Pfizer**

**July 2013 – January 2015**

Research Assistant

Assisted scientists at the oncology research unit in advancing early stage drug development of next generation ALK inhibitors. Examined the mechanism of cellular resistance to crizotinib. Screened compounds in cell based assays to determine rational combinations. Performed western blots to characterize target pathway inhibition. Generated and maintained

mammalian tumor cell lines.

**University of California, San Diego**

**March 2013 – June 2014**

Exam Proctor

As an exam proctor/grader, I worked alongside the professors of the chemistry and biochemistry department in administering and grading examinations. During examinations, I answer any questions a student might have pertaining to the exam, such as clarification of questions. I was also responsible for grading the exams and ensuring the questions were answered correctly and scored appropriately.

**The Scripps Research Institute**

**October 2011 – March 2013**

Research Lab Assistant

Assisted scientist in research of the regulation and function of cytochrome P450 proteins PPAR-alpha and 4A11. Responsibilities included running PCR reactions, purification of DNA from animal tissues, BCA assays, and making media/broths/ and solutions.

**Peer-Reviewed  
Publications**

Koh, M. Y., Gagea, M., **Sargis, T.**, Lemos, R., Grandjean, G., Charbono, A., Bekiaris, V., Sedy, J., Kiriakova, G., Liu, X., Roberts, L. R., Ware, C. and Powis, G. (2016), A new HIF-1 $\alpha$ /RANTES driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in Mice. *Hepatology*, 63: 1576–1591. doi:10.1002/hep.28468.

**Submitted  
Manuscripts**

**Sargis, T.**, Green, Y., Jonasch, E., Koh, M. (2018), Hypoxia Associated Factor (HAF) drives resistance to sorafenib in kidney cancer by promoting the ubiquitination of neurofibromin-1 (NF-1). Submitted Manuscript.

Qiu, M., Lee, N., Cao J., Wang H., Hendrickson E., **Sargis, T.**, Fan, C., Huang, D., Ozeck, M., Tsaparikos, K., Hook, K., Engstrom, L., Lam, J., Deng, S., Smeal, T., Rejto, P., Harwick, J. and Wei, P. (2017), Targeting mTOR or PI3Kalpha but not PI3Kbeta signaling axis enhances the response to ALK inhibitor lorlatinib in crizotinib-resistant EML4-ALK+ NSCLC models. Submitted Manuscript.

**Abstracts and  
Conference  
Presentations**

Chaudhri R, Herts J, **Sargis T**, Naiche L, Kitajewski J. Ligand-specific Notch decoys potential anti-angiogenic biotherapeutics. Proceedings of the 2018 International Vascular Biology Meeting; 2018 Jun 3-7; Helsinki, Fi.

Wei P, Qiu M, Lee N, Cao J, Wang H, Tsaparikos K, Fan C, **Sargis T**, Lam J, Lira M, Lui G, Hardwick J, Fantin V, Rejto P, Smeal T. (2015). Rational Combinations of PF-06463922 (Next Generation ALKi) with Other Targeted Therapies as a Strategy to Overcome Crizotinib Resistance in EML4-ALK+ NSCLC. Proceedings of the 106<sup>th</sup> Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Abstract nr 764.

**Leadership and  
Community  
Involvement**

**Sanford-Burnham-Prebys Building Community Committee**    **August 2016 – June 2017**  
Member

**SteppingUP S.T.E.M. Academy Career Day**  
Professional Volunteer

**October 2016**

**Discovery Science Center**  
Volunteer

**January 2011 – October 2011**

**Professional  
Memberships**

**American Association for Cancer Research**  
Associate

**May 2018 – Current**

**North American Vascular Biology Organization**  
Trainee

**June 2018 – Current**